Overview A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis Status: Not yet recruiting Trial end date: 2024-01-31 Target enrollment: Participant gender: Summary A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis Phase: Phase 2 Details Lead Sponsor: Taisho Pharmaceutical Co., Ltd.